A number of other equities research analysts have also recently commented on BLUE. Cantor Fitzgerald assumed coverage on shares of Bluebird Bio in a research report on Thursday, June 2nd. They set a hold rating and a $42.00 target price for the company. Maxim Group set a $85.00 target price on shares of Bluebird Bio and gave the company a buy rating in a research report on Thursday, September 22nd. Leerink Swann reissued a buy rating on shares of Bluebird Bio in a research report on Monday, June 13th. Vetr cut shares of Bluebird Bio from a strong-buy rating to a sell rating and set a $44.44 target price for the company. in a research report on Wednesday, June 8th. Finally, Wedbush reissued an outperform rating and set a $117.00 target price on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $90.25.
Bluebird Bio (NASDAQ:BLUE) opened at 69.55 on Friday. The stock’s market cap is $2.59 billion. The company’s 50 day moving average is $60.55 and its 200-day moving average is $49.62. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $2.01 million. During the same period in the previous year, the company earned ($1.57) EPS. The company’s revenue was down 68.6% on a year-over-year basis. Equities research analysts forecast that Bluebird Bio will post ($6.18) earnings per share for the current fiscal year.
In related news, insider Eric Sullivan sold 2,807 shares of the firm’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the sale, the insider now owns 4,656 shares in the company, valued at $209,706.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider David Davidson sold 1,000 shares of the firm’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the sale, the insider now owns 10,600 shares in the company, valued at approximately $477,848. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP purchased a new stake in Bluebird Bio during the first quarter valued at approximately $51,095,000. BlackRock Inc. increased its position in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the last quarter. California State Teachers Retirement System increased its position in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock valued at $3,363,000 after buying an additional 1,682 shares during the last quarter. Iguana Healthcare Management LLC bought a new position in Bluebird Bio during the first quarter valued at about $1,030,000. Finally, Swiss National Bank increased its position in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares during the last quarter.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.